US equities |
NVDA $221.30 ▼-3.16% MU $914.13 ▼-4.10% AAPL $342.96 ▲+0.50% AMD $570.82 ▼-5.73% META $737.54 ▼-3.27% MSFT $533.69 ▼-1.80% TSLA $367.16 ▼-2.15% SPCX $152.16 ▼-2.80%
FinancialContent

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

14.90 -0.02 (-0.13%)
Delayed Quote Updated: 4:00 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ultragenyx Pharmaceutical Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
17 18 Next >
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why WK Kellogg Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Ultragenyx, Mereo Sink After Hours As Bone Drug Trial Continues Without Early Stop; Retail Traders Feel Selloff Is Overdone ↗
The companies now expect final data from the Orbit and Cosmic studies by the end of the year. 
Via Stocktwits
News headline image
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 6, 2025 ↗
 
Via Benzinga
News headline image
Ultragenyx Pharmaceutical's Earnings: A Preview ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
What's going on in today's after hours session ↗
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis
Data from Orbit and Cosmic studies expected around the end of the year 
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Breaking Down Ultragenyx Pharmaceutical: 7 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Pharmaceutical Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028 ↗
Ultragenyx sees rising revenue and analyst support as key drug launch approaches, with potential profitability projected for 2027. 
Via Benzinga
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx to Participate at Bank of America’s 2025 Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
8 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Stays On JPMorgan's Focus List As Analyst Highlights Strong Long-Term Positioning ↗
JP Morgan sees strong upside for Ultragenyx, citing setrusumab trial progress and pipeline growth, raising the price target to $117. 
Via Benzinga
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Demystifying Ultragenyx Pharmaceutical: Insights From 10 Analyst Reviews ↗
 
Via Benzinga
News headline image
Ultragenyx to Participate at Investor Conferences in March
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
FDA decision expected by August 18, 2025 
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
17 18 Next >